Pharming (PHAR) Operating Expenses (2020 - 2026)
Pharming's (PHAR) quarterly Operating Expenses came in at -$88.0 million in Q2 2026, little changed YoY from -$88.1 million in Q2 2025, and down 115.78% on a QoQ basis from -$40.8 million in Q1 2026.
Pharming (PHAR) Operating Expenses (2020 - 2026) Analysis & Trends
Pharming (PHAR) has 7 years of Operating Expenses data on file, last reported at -$88.0 million in Q2 2026.
- Quarterly Operating Expenses changed 0.18% year-over-year to -$88.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$309.1 million (down 8.35% YoY) and the FY2025 annual result came in at $411.7 million, up 15.74% from the prior year.
- Operating Expenses fell to -$88.0 million in Q2 2026, from -$40.8 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of -$31.9 in Q2 2023 to a low of -$180.3 million in Q4 2025.
- A 5-year average of -$54.9 million and a median of -$37.2 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2023 — Operating Expenses surged 100.0% — and 2024, when it slumped 222021843.57%.
- Tracing PHAR's Operating Expenses over 5 years: stood at -$98.5 million in 2022, then soared by 100.0% to -$89.2 in 2023, then tumbled by 172418061.43% to -$153.8 million in 2024, then declined by 17.25% to -$180.3 million in 2025, then surged by 51.21% to -$88.0 million in 2026.
- The last three Operating Expenses figures came in at -$88.0 million (Q2 2026), -$40.8 million (Q1 2026), and -$180.3 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn | -87.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -87.98 Mn |
| Mar 31, 2026 | -40.77 Mn |
| Dec 31, 2025 | -180.33 Mn |
| Sep 30, 2025 | -40.40 |
| Jun 30, 2025 | -87.83 Mn |
| Mar 31, 2025 | -43.63 Mn |
| Dec 31, 2024 | -153.80 Mn |
| Sep 30, 2024 | -36.00 |
| Jun 30, 2024 | -70.83 Mn |
| Mar 31, 2024 | -33.61 Mn |
| Dec 31, 2023 | -89.20 |
| Sep 30, 2023 | -31.64 Mn |
| Jun 30, 2023 | -31.90 |
| Mar 31, 2023 | -25.60 Mn |
| Dec 31, 2022 | -98.50 Mn |
| Sep 30, 2022 | -24.30 Mn |
| Dec 31, 2021 | 57.27 Mn |
| Sep 30, 2021 | -20.75 Mn |
| Dec 31, 2020 | 44.62 Mn |
| Sep 30, 2020 | -14.69 Mn |